Label Battles: Beovu And Eylea Contest Begins In AMD
Novartis's injectable anti-VEGF Beovu was approved for wet AMD by the US FDA
Shares in Eylea-maker Regeneron slid after FDA approved Novartis's competing VEGF inhibitor for treating AMD, but some observers said investors had overreacted.
You may also be interested in...
Tschudin talked to Scrip about taking over as Novartis Pharmaceuticals president, why inclisiran is different from marketed PCSK9 inhibitors and prioritizing investment behind multiple new launches.
The New York-headquartered firm, which recently decided to focus on gene therapy, has to decide whether to partner Zimura or go it alone.
Pharmaceutical sales hit €4.35bn helped by a strong showing in China but as the number of glyphosate plaintiffs in the US jumps to 42,700, the German group's priority is sorting out Monsanto.